According to Syndax Pharmaceuticals's latest financial reports the company has โน34.56 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | โน48.08 B | 19.96% |
2022-12-31 | โน40.08 B | 20.52% |
2021-12-31 | โน33.25 B | 55.17% |
2020-12-31 | โน21.43 B | 402.81% |
2019-12-31 | โน4.26 B | -24.66% |
2018-12-31 | โน5.65 B | -31.83% |
2017-12-31 | โน8.29 B | 15.94% |
2016-12-31 | โน7.15 B | 24.53% |
2015-12-31 | โน5.74 B | 642.86% |
2014-12-31 | โน0.77 B | -12.2% |
2013-12-31 | โน0.88 B | 2462.84% |
2012-12-31 | โน34.38 M |